February 20, 2014. We believe that the device under review today may represent a novel way to improve the lives of patients who are not effectively treated by CPAP. However, we have 2 concerns.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Letter Regarding Coalition Concerns about H.R. 3742, the Antibiotic Development to Advance Patient Treatment (ADAPT) Act of 2013
February 20, 2014. As members of the Patient, Consumer, and Public Health Coalition, which includes groups representing physicians, scientists, consumers, and patients, we are writing to express our concerns about H.R. 3742, the Antibiotic Development to Advance Patient Treatment (ADAPT) Act of 2013.
Read More »NCHR Testimony to FDA Advisory Committee on Iontophoresis Devices
February 21, 2014. Class III devices are defined by “potential unreasonable risk of illness or injury”. Based on that definition and the information that was provided to the committee and the public for this meeting, we are convinced, as FDA was for 2 decades, that iontophoresis devices are Class III devices that should be reviewed under the more rigorous PMA process.
Read More »Letter of Opposition for the Preventing Regulatory Overreach To Enhance Care Technology (PROTECT) Act of 2014
February 14, 2014. As members of the Patient, Consumer, and Public Health Coalition, we strongly oppose the Preventing Regulatory Overrreach To Enhance Care Technology (PROTECT) Act of 2014.
Read More »NCHR Testimony on the Platelet Inhibitor Drug, Cangrelor
February 12, 2014. Testimony of Laurén Doamekpor, Senior Fellow with NCHR, on Cangrelor to the FDA Cardiovascular and Renal Drugs Advisory Committee.
Read More »